Thursday, June 16, 2022

Biogen RTP Bio Facility Recertified as Carolina Star Site for Exceptional Safety Record

Research Triangle Park
Jun 16, 2022

Biogen RTP Bio was recognized for their outstanding safety record by being recertified for a second time as a Carolina Star Site at the Research Triangle Park (RTP) facility on Thursday, May 26. Labor Commissioner Josh Dobson provided keynote remarks and commended Biogen for its continued commitment to workplace health and safety.  

“We don’t just give out these awards—they have to be earned. All of you have put in the hard work to earn this award, and that’s worth celebrating,” Commissioner Dobson said. “North Carolina’s reputation for safe workplaces makes us unique. The culture you’ve created at Biogen is a critical part of continuing and building upon that reputation.”

A comprehensive evaluation was conducted at the RTP facility by the North Carolina Department of Labor Carolina Star Team to determine Biogen RTP Bio’s eligibility for recertification. Eligibility for Carolina Star certification requires submitting a Star Annual Report, which includes three-year averages of annual Total Recordable Case (TRC) rate and Days Away, Restricted or Transferred (DART) rate data.

Biogen’s three-year average TRC rate for 2018-2020 was 55% below the comparable rate for its industry and its DART case rate was 67% below the comparable industry rate as well. The minimum DART and TRC rates must be 50% below comparable industry averages to receive and maintain Carolina Star status.

As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp.

Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipeline in neuroscience that will transform the standard of care for patients in several areas of high unmet need. 

In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes and support underserved communities.

Related Topics: